Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5 CAR-T for Refractory/Relapsed CD5+ T-ALL
NCT05596266Phase 1Unknown
- Sponsor
- Xuanwu Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD5 CAR-T (Xuanwu Hospital) in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Xuanwu Hospital. Primary endpoint: Incidence and severity of adverse events at 1 month. Status: unknown.
02
Drugs
CD5 CAR-T (Xuanwu Hospital)
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT05596266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05596266.